TY  - JOUR
A1  - Mombo-Ngoma, Ghyslain
A1  - Kleine, Christian
A1  - Basra, Arti
A1  - Würbel, Heike
A1  - Diop, Daisy A.
A1  - Capan, Mesküre
A1  - Adegnika, Ayola A.
A1  - Kurth, Florian Michael
A1  - Mordmüller, Benjamin Gottlieb
A1  - Joanny, Fanny
A1  - Kremsner, Peter G.
A1  - Ramharter, Michael
A1  - Bélard, Sabine
T1  - Prospective evaluation of artemether-lumefantrine for the treatment of non-falciparum and mixed-species malaria in Gabon
T2  - Malaria journal : published in collaboration with the Liverpool School of Tropical Medicine
N2  - Background: The recommendation of artemisinin combination therapy (ACT) as first-line treatment for uncomplicated falciparum malaria is supported by a plethora of high quality clinical trials. However, their recommendation for the treatment of mixed-species malaria and the large-scale use for the treatment of non-falciparum malaria in endemic regions is based on anecdotal rather than systematic clinical evidence.
Methods: This study prospectively observed the efficacy of artemether-lumefantrine for the treatment of uncomplicated non-falciparum or mixed-species malaria in two routine district hospitals in the Central African country of Gabon.
Results: Forty patients suffering from uncomplicated Plasmodium malariae, Plasmodium ovale or mixed-species malaria (including Plasmodium falciparum) presenting at the hospital received artemether-lumefantrine treatment and were followed up. All evaluable patients (n = 38) showed an adequate clinical and parasitological response on Day 28 after oral treatment with artemether-lumefantrine (95% confidence interval: 0.91,1). All adverse events were of mild to moderate intensity and completely resolved by the end of study.
Conclusions: This first systematic assessment of artemether-lumefantrine treatment for P. malariae, P. ovale and mixed-species malaria demonstrated a high cure rate of 100% and a favourable tolerability profile, and thus lends support to the practice of treating non-falciparum or mixed-species malaria, or all cases of malaria without definite species differentiation, with artemether-lumefantrine in Gabon.
Trial Registration: ClinicalTrials.gov Identifier: NCT00725777
KW  - Malaria
KW  - Ovale
KW  - Malariae
KW  - Artemisinin-combination-therapy
KW  - Artemether-lumefantrine
KW  - Non-falciparum
Y1  - 2012
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/31666
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-316665
SN  - 1475-2875
N1  - © 2012 Mombo-Ngoma et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
VL  - 11
IS  - 120
PB  - BioMed Central
CY  - London
ER  -